Correction: Brüning-Richardson et al. GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. <i>Cancers</i> 2021, <i>13</i>, 5939.

Brüning-Richardson, Anke; Shaw, Gary C; Tams, Daniel; Brend, Tim; Sanganee, Hitesh; Barry, Simon T; Hamm, Gregory; Goodwin, Richard J A; Swales, John G; King, Henry; Steele, Lynette; Morton, Ruth; Widyadari, Anastasia; Ward, Thomas A; Esteves, Filomena; Boissinot, Marjorie; Mavria, Georgia; Droop, Alastair; Lawler, Sean E; Short, Susan C

Correction: Brüning-Richardson et al. GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. Cancers 2021, 13, 5939.

Brüning-Richardson, Anke; Shaw, Gary C; Tams, Daniel; Brend, Tim; Sanganee, Hitesh; Barry, Simon T; Hamm, Gregory; Goodwin, Richard J A; Swales, John G; King, Henry; Steele, Lynette; Morton, Ruth; Widyadari, Anastasia; Ward, Thomas A; Esteves, Filomena; Boissinot, Marjorie; Mavria, Georgia; Droop, Alastair; Lawler, Sean E; Short, Susan C.

Afiliação

Brüning-Richardson A; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Shaw GC; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Tams D; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Brend T; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Sanganee H; Discovery Sciences BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 8PA, UK.
Barry ST; Bioscience, Early Oncology, Oncology R&D, AstraZeneca, Cambridge CB2 8PA, UK.
Hamm G; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 8PA, UK.
Goodwin RJA; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 8PA, UK.
Swales JG; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 8PA, UK.
King H; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Steele L; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Morton R; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Widyadari A; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Ward TA; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Esteves F; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Boissinot M; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Mavria G; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.
Droop A; Leeds MRC Medical Bioinformatics Centre, University of Leeds, Leeds LS9 7TF, UK.
Lawler SE; Pathology & Laboratory Medicine, Brown University Cancer Center, Brown University, Providence, RI 02903, USA.
Short SC; Leeds Institute of Medical Research at St James's, University of Leeds, Leeds LS9 7TF, UK.

Cancers (Basel) ; 14(15)2022 Aug 04.

Article em En | MEDLINE | ID: mdl-35954505

ABSTRACT

ABSTRACT

The authors wish to make the following corrections to this paper [1][...].

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido